A Real-World, Prospective, Observational Study of Rivaroxaban on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-Valvular Atrial Fibrillation: XARENAL
Open Access
- 1 January 2025
- journal article
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (2) , 121-131
Abstract
Oh IY, et al. Korean Circ J. 2024 Oct;55:e8. https://doi.org/10.4070/kcj.2024.0154Keywords
Funding Information
- Bayer Korea
This publication has 29 references indexed in Scilit:
- XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in AsiaAdvances in Therapy, 2022
- Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AFTH Open, 2021
- XANAP: A real‐world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in AsiaJournal of Arrhythmia, 2018
- 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort studyThe Lancet, 2015
- Oral anticoagulants for Asian patients with atrial fibrillationNature Reviews Cardiology, 2014
- The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillationJournal of Arrhythmia, 2013
- Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney DiseaseNew England Journal of Medicine, 2012
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Warfarin TherapyNew England Journal of Medicine, 1970